RT Book, Section
A1 Papadakis, Maxine A.
A1 McPhee, Stephen J.
A1 Rabow, Michael W.
A1 McQuaid, Kenneth R.
SR Print(0)
ID 1193123736
T1 Pulmonary Disorders Year in Review
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193123736
RD 2024/04/19
AB For  patients  with  frequent  exacerbations,  the  use  of  biologic  agents,  such  as  anti-IgE  (omalizumab),  anti-IL-5  (mepolizumab,  benralizumab),  or  anti-IL4  receptor  (dupilumab),  has  been  shown  to  improve  outcomes.